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Biomarkers may be characterized as diagnostic, distinguishing 
between two states (say, infected or non-infected); prognostic, 
informing of a likely outcome (say, mortality); or predictive, if a 
treatment effect is differential between biomarker positivity and 
negativity [1]. One of the most discussed biomarkers in the infectious 
diseases and critical care literature is procalcitonin [2-4],  a polypeptide 
that serves as the precursor for calcitonin in thyroid gland C cells 
and is released in response to microbial toxins and pro-inflammatory 
mediators [5]. Procalcitonin qualifies as both a diagnostic (an infection 
or sepsis marker) and predictive (a guide to antimicrobial therapy) 
biomarker. This being said, procalcitonin biomarker performance 
has been subjected to a large number of meta-analyses [6-20], 
suggesting a degree of disquiet regarding the actual level of evidence 
for procalcitonin utility. 
We first summarize certain key parameters of procalcitonin 
performance as a diagnostic biomarker in 6 meta-analyses, conducted 
between the years of 2004-2015; author sub-group analyses are not 
considered (Table 1) [11,14,16-19]. Where reported, heterogeneity 
was a marked feature, even when restricted to a more circumscribed 
population of the “critically ill”; the components of heterogeneity 
presumably reflecting such factors as different procalcitonin assays and 
threshold levels, patient subgroups, endpoint prevalence, primary study 
inclusions and exclusions, and study quality / bias [5]. Analytic methods 
reflected year of publication, with the earlier studies [16-19] using the 
linear regression model of  Moses et al, as opposed to the mixed-effects 
bivariate approach of the two more recent studies [11,14]; a point of 
importance for Wacker and co-authors [14]. Overall, the diagnostic 
performance could at best be described as modest, a point conceded by 
some of the authors [11, 16, 18] and reiterated by Afshari and Harbath 
[22], commenting upon the somewhat fulsome conclusions of  Wacker 
et al. [14]. The former noted that the sensitivity of 77% corresponded 
to 23% of patients not receiving adequate therapy and a specificity 
of 79% corresponded to 21% being unnecessarily treated (Table 1); 
similarly, a positive likelihood ratio of 3.67 and a negative likelihood 
ratio of 0.29, being small and containing no information,  were “… 
of little use for guiding initial treatment decisions”, especially in the 
critically ill with a high pre-test sepsis probability [22]. As diagnostic 
meta-analyses have had a history of poor reporting [23]  compared with 
meta-analyses reporting treatment effects of randomized controlled 
trials, the attendant vigorous correspondence [22, 24-29] to some of the 
above meta-analyses is perhaps not surprising. 
One outstanding feature of these diagnostic meta-analyses was the 
variable cut-point procalcitonin thresholds used in the primary studies. 
Again in a response to the meta-analysis of Wacker et al. [14], Ruecker 
and Schumacher [28] suggested, in agreement with a preliminary 
observation by Wacker et al, that  “investigators of the primary studies 
seemed to select cutoffs such that they maximised the sum of sensitivity 
and specificity”. They further elaborated an analysis that modelled 
the assumption that the investigators of the primary studies selected 
their cutoff such that it maximised a weighted sum of sensitivity (Se) 
and specificity (Sp): ( ).Se + 1 .Spλ λ− ; λ  (between 0 and 1) was the 
weight the study investigators attributed to the sensitivity and a λ  of 
0·5 attributed equal weights to sensitivity and specificity, equivalent to 
maximisation of the Youden index. The estimate of λ  was 0.491, quite 
close to 0.5, supporting their initial hypothesis. Estimates of pooled 
sensitivity and specificity were 0.72 and 0.73, even less that those 
estimates subjected to critique by Afshari and Harbath [22]. In a more 
recent study Steinhauser et al [30] proposed to model the distribution 
functions of the underlying biomarker by applying a linear mixed effects 
model, accounting for a cross-study heterogeneity and dependence  (or 
correlation) of sensitivity and specificity. That is, an attempt was made 
to utilize all of the available information. Again accessing data from 
the meta-analysis of Wacker et al. [14], 54 data points in total for 26 
different values of the procalcitonin thresholds were obtained, yielding 
a model sensitivity of 0.71 (0.63; 0.78) and a specificity of 0.81 (0.74; 
0.86], similar to the previous estimates of Ruecker and Schumacher 
[28]. The estimated optimal threshold for procalcitonin in this analysis 
was 1.2 ng/ml. Such an approach to the problem of multiple diagnostic 
thresholds appears to be a most promising initiative  and has been 
implemented in at least one independent study [31].
Given that procalcitonin as a diagnostic biomarker for sepsis / 
infection has consistently failed to achieve sensitivities and specificities 
above 80% (Table 1), it may be surprising that its use has been 
incorporated into a number of randomized controlled trials as an 
antibiotic stewardship guide. How are we to understand this? As with 
any biological variable, single measurements will be subject to random 
variability and measurement error, potentially generating regression 
dilution bias and regression to the mean, and repeated measurement 
would be, prima facie, preferable [32].  Thus algorithms incorporating 
time-dependent (daily or otherwise) procalcitonin assays have 
been incorporated into decision-making with respect to anti-biotic 
prescription [33]. 
The accumulation of RCTs over time obviously limits a definitive 
answer to the utility of procalcitonin as a predictive biomarker. We 
Moran JL (2017) Procalcitonin as a biomarker for infection and sepsis: Yet again
Pulm Crit Care Med, 2017         doi: 10.15761/PCCM.1000135  Volume 2(2): 2-3
present snapshots at the publication juncture of two reviews; by Pavoa 
and Sullah in 2012  and Andrioli and co-workers in 2017  [6,34]. The 
former reviewers cited 7 randomized controlled trials (2007 to 2011) 
assessing the role of procalcitonin-guided antibiotic stewardship 
in adult critically ill patients. Despite repeated association of this 
stewardship with a decrease in the duration of antibiotic therapy, 
the authors identified several trial limitations; high rate of patient 
exclusion and algorithm overruling, long duration of antibiotic 
therapy in the control group, disregarding of the effect of renal failure 
on procalcitonin level, and possible higher mortality and higher late 
organ failure in the procalcitonin arm. They concluded that the role 
of procalcitonin-guided antibiotic stewardship was “uncertain” [34]. 
Andrioli et al identified 10 trials with 1215 participants (search date 
to July 2015) and were more forthright in their conclusions: “Up-to-
date evidence of very low to moderate quality, with insufficient sample 
power per outcome, does not clearly support the use of procalcitonin-
guided antimicrobial therapy to minimize mortality, mechanical 
ventilation, clinical severity, reinfection or duration of antimicrobial 
therapy of patients with septic conditions” [6].  However the authors 
reported a second search in October 2016 and identified 3 further trials 
(not included in their analysis) with a total of 2695 participants; two 
multi-site and one single-centre [35-37].  It is not the purpose of this 
paper to conduct yet another meta-analysis of the use of procalcitonin; 
a simple search conducted using Web of Science™ on June 26th with 
the terms “procalcitonin” and “meta-analysis” identified 191 hits. We 
suffice to summarize the results of the two multi-site trials.  Bloos et al. 
recruited 1089 patients with severe sepsis or septic shock and found no 
mortality effect of procalcitonin-guided antimicrobial therapy, but a 
reduction of antibiotic exposure by 4.5%, with no influence on resource 
utilization. They concluded that “The application of a procalcitonin-
guided algorithm needs further evaluation” [35].  De Jong et al [36] 
enrolled 1546 critically ill patients with assumed or proven infection 
and found an unexpected 5.4% (p=0.01) 28-day mortality reduction 
and a decrease in both antibiotic consumption and treatment duration 
with procalcitonin-guided antimicrobial therapy. Of interest, the 
mean per patient saving in antibiotic costs of €34 (with an average of 
7 procalcitonin measurements per patient) had a break-even cost for 
procalcitonin of  less than €4 per measurement. At the hospital of the 
authors of this paper the cost per measurement is €38. Again, adherence 
to the antibiotic stopping rules was variable (40-50%) in both studies.
Where do we stand? A single procalcitonin measurement in, say, 
the emergency department or intensive care unit of a hospital would 
not appear to be of benefit in guiding decision making for diagnosis and 
therapy of infection/sepsis. The benefits or otherwise of procalcitonin-
guided antimicrobial therapy are still uncertain and would appear to 
depend upon the cost and medical structure of each jurisdiction.
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